Paper Details

  1. Home
  2. Paper Details

Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial.

Author: , AmblerGareth, BunceCatey, GazzardGus, VickerstaffVictoria, XingWen

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This multicenter randomized controlled trial (LiGHT) compares two treatment pathways for newly diagnosed open-angle glaucoma (OAG) and ocular hypertension (OHT): selective laser trabeculoplasty (SLT) as the primary treatment ('Laser-1st') versus IOP-lowering drops ('Medicine-1st').
Paper Details　
Original Abstract of the Article :
The LiGHT trial (Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial) is a multicentre randomised controlled trial of two treatment pathways for patients who are newly diagnosed with open-angle glaucoma (OAG) and ocular hypertension (OHT). The main hypothesis for the trial is that ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642765/

データ提供：米国国立医学図書館（NLM）

Laser vs. Drops: A Desert of Treatment Options for Glaucoma

Glaucoma, a group of eye conditions that can damage the optic nerve, is a leading cause of irreversible blindness. This study outlines the statistical analysis plan for a multicenter randomized controlled trial, known as LiGHT (Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial). The trial aims to compare two treatment pathways for newly diagnosed patients with open-angle glaucoma and ocular hypertension: selective laser trabeculoplasty (SLT) as the primary treatment (Laser-1st) versus IOP-lowering drops as the primary treatment (Medicine-1st). The study will assess the impact of these treatment pathways on health-related quality of life, costs, and treatment tolerability. This trial promises to provide valuable insights into the optimal management of glaucoma and ocular hypertension.

Finding the Best Oasis for Glaucoma Treatment

This trial represents a significant step forward in the quest for effective and patient-centered approaches to glaucoma management. The findings will help to determine the most appropriate treatment pathway for individuals with this complex eye condition. This study is likely to have a significant impact on clinical practice and improve the care of patients with glaucoma and ocular hypertension.

Navigating the Desert of Vision Loss

If you have been diagnosed with glaucoma or ocular hypertension, it's crucial to consult with a healthcare professional to discuss treatment options and develop a personalized plan. This trial highlights the importance of exploring different approaches to ensure you receive the best possible care for your vision.

Dr.Camel's Conclusion

This study, like a camel caravan embarking on a long journey, sets out to explore the vast and often challenging desert of glaucoma treatment. By comparing two distinct treatment pathways, the researchers hope to find the most effective and tolerable oasis for those affected by this complex eye condition. The findings will be crucial for guiding clinical practice and improving the care of patients with glaucoma and ocular hypertension.

Date :
  1. Date Completed 2016-07-11
  2. Date Revised 2021-01-09
Further Info :

Pubmed ID

26559142

DOI: Digital Object Identifier

PMC4642765

Related Literature

Article Analysis
・Effective treatment of glaucoma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.